The Prevention and Treatment of Select Viral Infections is a new DR Report from Decision Resources that evaluates the current and future status of therapeutic and prophylactic drugs and vaccines in development for six major viruses: human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), and varicella-zoster virus (VZV).

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Despite some progress, significant unmet needs remain in the field of antivirals -- for more effective and less toxic therapeutic agents to treat patients who are already infected and for prophylactic vaccines against new infections. The combination of large patient populations and unmet needs has created a dynamic and potentially lucrative market opportunity for pharmaceutical and biopharmaceutical companies competing in this field.

The six viruses under study differ markedly in incidence and in the severity of the diseases they cause. In addition, treatment of the diseases these viruses cause is characterized by substantial differences in therapeutic approach and levels of unmet need, for which numerous antiviral products are under development. Our analysis of these therapies leads us to conclude that the fastest-growing segment will be anti-HCV therapies. Growth drivers in the anti-HCV market include the following:

  * Rising diagnosis rates as both clinicians and patients become more aware     of the disease.   * Increasing numbers of HCV-infected people who will become symptomatic     over the next five years.   * Availability and uptake of new, more-effective drug therapies.  

We also forecast substantial market opportunities for anti-HBV and anti- HIV drugs, driven by the fact that these viruses require prolonged drug treatment and the constant need for new drug therapies that are not susceptible to current mechanisms of resistance.

The Prevention and Treatment of Select Viral Infections is a DR Report published by Decision Resources, Inc. This report is available for $4,250.00.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

Contact Tim Daley, 781.296.2636 (tel), 781.296.2550 (fax), or tdaley@dresources.com.

In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be.

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X24743874

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Tim Daley of Decision Resources, Inc., +1-781-296-2636, or
tdaley@dresources.com

The Hyperlipidemia Drug Market Responds to New Guidelines and the Cerivastatin Withdrawal

View Now